---
schema_version: "secwatch.filing_event.v1"
accession: "0001299130-22-000128"
form_type: "8-K"
ticker: "PACB"
cik: "0001299130"
company_name: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:03:54.124771+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PacBio Q3 2022 revenue down 7% YoY to $32.3M; net loss $77M; withdraws guidance; launches Revio and Onso systems

## Summary
- Revenue $32.3M (down 7% YoY); instrument revenue $11.4M (down 28%); consumables revenue $16.1M (up 10%).
- GAAP net loss $77.0M ($0.34 EPS) vs net income $16.5M ($0.08 EPS) in Q3 2021; non-GAAP net loss $72.5M ($0.32 EPS).
- Cash and investments $834.3M, down from $1,044.4M at Dec 2021; withdrawn all prior financial guidance.
- Launched Revio long-read system (up to 1,300 human genomes/year, <$1k/genome) with shipments starting Q1 2023.
- Introduced Onso short-read system with 10x accuracy improvement; shipments expected H1 2023.

## SEC filing metadata
- accession: 0001299130-22-000128
- form_type: 8-K
- ticker: PACB
- cik: 0001299130
- company_name: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/0001299130-22-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001299130-22-000128
- JSON: https://secwatch.observer/filing/0001299130-22-000128.json
- Plain text: https://secwatch.observer/filing/0001299130-22-000128.txt

## Key facts
- Earnings Releases
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported third quarter ended September 30, 2022 results: revenue $32.3 million, net income $77.0 million, EPS $0.34.
  - Period: third quarter ended September 30, 2022
  - Revenue: $32.3 million
  - Net income: $77.0 million
  - EPS: $0.34
  - Result: reported results
  source text: Menlo Park, Calif. – November 7, 2022 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results · Revenue of $32.3 million, a 7% decrease compared with $34.9 million in the prior year period. · Instrument revenue of $11.4 million, compared with $15.9 million in the prior year period. · Consumables
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/0001299130-22-000128-index.htm
- Governance Changes
  PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: Amended and restated Second Amended and Restated Bylaws to revise director nomination and stockholder proposal procedures, conform to DGCL, update provisions on directors/committees/officers, clarify forum selection, and make ministerial updates (effective 2022-11-03).
  - Change: bylaw amendment
  - Effective: 2022-11-03
  source text: On November 3, 2022, the Company’s board of directors, upon recommendation of the corporate governance and nominating committee, amended and restated the Company’s Second Amended and Restated Bylaws, effective immediately (the “Amended and Restated Bylaws”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/0001299130-22-000128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.